Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (567)	6/11/1999 3:13:00 AM
From: Mike McFarland	Respond to of 4474

And the last 100... one to read, Peter really hit the nail on the head here: Message 7712822 (snip) The real issue is that a deal like this creates fear and uncertainty among the shareholders and adds considerable financial complexity to the existing scientific complexity. For the next few years, the shareholders are likely going to be like restless kids on a long trip, forever whining "are they converted yet?" Of course none of the above means that the company can't dig itself out of this financing hole by producing a spectacular partnership, deal or product. --Peter If the underlying fundamentals of the company improve, the floorless becomes much less significant. If they deteriorate, watch out below! ARIAD Receives Third Patent for Pharmaceutical Regulation of Cell Activity- I'm feeling a bit deflated after a fella on the yahoo board got all snotty about the level of noise he has to endure when he reads SI. ARIA registers shares to cover the conversion of the floorless convertible. Second Milestone in Bone Disease Collaboration Which is more important: great science or rotten financing? something that was pissing me off, and so I took 1500 of my 3000 Ariad off the table There is an excellent article on Dr. James Wilson and the gene therapy work being done at the U. of Pennsylvania in today's NY Times. It is on page 1 on the Science Section. Get the paper if possible as there is a neat illustration and a photo of Dr. Wilson. Ariad's involvement is mentioned. ARIA today announced the issuance of the fourth in a series of patents covering pharmaceutical regulation of fundamental cellular processes through protein dimerization. February Short positions in ARIA Double ARIA registers 5.9 million shares to cover preferred conversions Ariad appointed new CSO on March 4, replacing well respected scientist Michael Gilman ARIA short interest increases by 25% Possible role of NF-kB and p53 in the glutamate induced pro-apoptotic neuronal pathway ARIAD patent (U.S. Patent No. 5,871,753, issued on February 16, 1999) cover Dimerizer Drugs(TM) that bind to certain immunophilin or cyclophilin proteins. Such drugs are useful in regulating biological activity of genetically engineered cells. NF-kB regulates a wide range of critical genes including those involved in cell growth control and in immune and inflammatory responses. In addition, NF-kB is a critical regulator of HIV gene expression. NFkB up-regulates expression of numerous cytokines including TNF, IL-1, IL-6, IL-8, VCAM, ICAM A Mickey Mouse boutique lab, even with talented scientists toiling away, will not rise up to be a pharmaceutical company over night. The Ariad story is over. since the market knows ARIA can't do it, the game is now to let ARIA bleed to death so it won't have any bargaining power in selling off it's assets. ARIAD Completes Phase 1 Clinical Trial On Gene Regulation Drug to Treat Graft-Versus-Host Disease Q1 Results out. $5 million loss, $15.9 million cash left. I'd hoped that out of aria, ntii, cnsi, ctii--all that third tier cheap stuff I'm locked up in--that something would have paid off by now. Thus a little bit of GvHD in leukemic patients may actually be desirable. Completely depleting donor bone marrow of T-cells has not only reduced the incidence of GvHD, but has resulted in relapse rates as high as 65% among certain subsets of leukemic patients studied." The warrants are extended till 12/30/99 Buy recommendation by Bridge Technologies LLC from what I see in the annual it could go on as long as September. No, it's time to just throw in the towel and try and talk this one down even lower through September... Because they (ariaw) are not worth a dime, Mike. ____ The End.

To: Mike McFarland who wrote (567)	6/11/1999 9:28:00 PM
From: John Dwyer	Respond to of 4474

Thanks for the thread recap... reminded me of one of those VH1 behind the scenes stories about a great rock band that had several #1 hits and then fell on hard times. I still hold a couple thousand shares and don't plan to sell them. Even with Gilman's departure (a bad sign, IMO) I think that the technology is worth more than the market cap. If somebody takes them out on the cheap, so be it. I bought some more Axys this week... another company with really good science that is going nowhere. Sibia was tempting below $4 but I passed. I really think that a few of these will succeed and be huge winners. The key, as I and others have said, is to own a basket of these guys in an otherwise diversified portfolio. John